The Current Ratio as of November 2024 (TTM) for IGM Biosciences, Inc. (IGMS) is 7.06

According to IGM Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.06. This represents a change of -13.05% compared to the average of 8.13 of the last 4 quarters.

IGM Biosciences, Inc. (IGMS) Historical Current Ratio (quarterly & annually)

How has IGMS Current Ratio performed in the past?

The mean historical Current Ratio of IGM Biosciences, Inc. over the last ten years is 10.76. The current 7.06 Current Ratio has changed 6.47% with respect to the historical average. Over the past ten years (40 quarters), IGMS's Current Ratio was at its highest in in the September 2019 quarter at 38.62. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

IGM Biosciences, Inc. (IGMS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of IGM Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

IGM Biosciences, Inc. (IGMS) Average Current Ratio

How has IGMS Current Ratio performed in the past?

The current Current Ratio of IGM Biosciences, Inc. (IGMS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

IGM Biosciences, Inc. (IGMS) Current Ratio vs. Peers

How is IGMS’s Current Ratio compared to its peers?

IGM Biosciences, Inc.’s Current Ratio is less than Avidity Biosciences, Inc. (15.78), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Cullinan Oncology, Inc. (28.87), less than Mineralys Therapeutics, Inc. (11.20), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), less than Erasca, Inc. (16.79), greater than TCR2 Therapeutics Inc. (2.96), less than Revolution Medicines, Inc. (15.42), greater than Black Diamond Therapeutics, Inc. (6.87), greater than Atreca, Inc. (1.58), less than Passage Bio, Inc. (7.67),

Build a custom stock screener for IGM Biosciences, Inc. (IGMS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IGM Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

IGM Biosciences, Inc. (IGMS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like IGM Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.